Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia
NCT03874858 · Novartis Pharmaceuticals · PHASE2 · terminated · last registry update 2026-07-13 · Chronic myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision: The primary endpoint of the core/TF1 was achieved, and the sample size of Extension/TFR2 was unlikely to yield meaningful results. No new safety signals were observed. For these reasons, continuing the study was not justified.” | Open Targets' class: negative | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ABL1 in chronic myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-29Phase 3 first posted: Enliven Therapeutics, ELVN-001 + TKI (NCT07905183)
- 2026-10-29Results posted on the registry: Novartis Pharmaceuticals, imatinib mesylate (NCT01742299)
- 2026-10-21Phase 3 first posted: Jiangsu Hansoh Pharmaceutical Co., Ltd., HS-10382 + Imatinib (NCT07885293)
- 2026-05-29Also stopped (terminated): Sarit Assouline, Asciminib + Imatinib (NCT05413915)
- 2026-05-27Results posted on the registry: Novartis Pharmaceuticals, Asciminib + Nilotinib (NCT05456191)
- 2026-05-13Results posted on the registry: Sun Pharma Advanced Research Company Limited, Vodobatinib (K0706) capsules (NCT02629692)
- 2026-05-13Also stopped (terminated): Sun Pharma Advanced Research Company Limited, Vodobatinib (K0706) capsules (NCT02629692)
- 2026-03-02Also stopped (terminated): M.D. Anderson Cancer Center, Asciminib (NCT04216563)
- 2026-01-15Results posted on the registry: M.D. Anderson Cancer Center, Dasatinib (NCT00254423)
- 2026-01-09Results posted on the registry: M.D. Anderson Cancer Center, Asciminib (NCT04216563)
- 2025-12-18Results posted on the registry: SWOG Cancer Research Network, Bosutinib + Dasatinib (NCT03654768)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision